New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Bright Minds Biosciences

Contributing Author

Recent Articles by Bright Minds Biosciences

Feb-25	Bright Minds Biosciences to Present at Upcoming Conferences DRUG -5.00% DRUG GlobeNewswire
Jan-09	Bright Minds Biosciences Announces Closing of US$175 Million Public Offering DRUG GlobeNewswire
Jan-07	Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock DRUG -6.22% GlobeNewswire
Jan-06	Bright Minds Biosciences Announces Launch of US$100 Million Public Offering DRUG +16.50% GlobeNewswire
Jan-06	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) DRUG +16.50% GlobeNewswire
Jan-05	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 DRUG GlobeNewswire
Nov-25	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting DRUG +8.37% GlobeNewswire
Nov-17	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) DRUG GlobeNewswire
Nov-06	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH DRUG +7.55% GlobeNewswire
Oct-30	Bright Minds Biosciences to Present at Upcoming Conferences DRUG GlobeNewswire
Sep-04	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model DRUG GlobeNewswire
Aug-25	Bright Minds Biosciences to Present at Upcoming Conferences DRUG -5.14% GlobeNewswire
May-28	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference DRUG GlobeNewswire
May-20	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 DRUG GlobeNewswire
May-13	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 DRUG GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)